Non-invasive assessment of tumor hypoxia using 123I-IAZA
Author Information
Author(s): M.B. Parliament, J.D. Chapman, R.C. Urtasun, A.J. McEwan, L. Golberg, J.R. Mercer, R.H. Mannan, L.I. Wiebe
Primary Institution: Cross Cancer Institute, University of Alberta
Hypothesis
Can 123I-iodoazomycin arabinoside (123I-IAZA) serve as a non-invasive marker for tumor hypoxia?
Conclusion
The study suggests that 123I-IAZA can be used as a non-invasive measure of tumor hypoxia, but further confirmation is needed.
Supporting Evidence
- Three out of ten tumors showed radiotracer avidity.
- T/N ratios increased over time in tumors showing uptake.
- 123I-IAZA was well tolerated with minimal toxicity.
Takeaway
Doctors are trying to find a way to see if tumors are low on oxygen without doing painful tests. They think a special medicine might help them do that.
Methodology
Patients with advanced malignancies received 123I-IAZA and underwent imaging to assess tumor uptake and biodistribution.
Potential Biases
No correlation was seen between 123I-IAZA dose and uptake, which may indicate bias in treatment effects.
Limitations
The study has a small sample size and a heterogeneous patient population.
Participant Demographics
Patients had advanced solid tumors including small cell lung cancer, malignant melanoma, and glioblastoma, with ages ranging from 47 to 75.
Want to read the original?
Access the complete publication on the publisher's website